Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. LICENSE AGREEMENT Dated December 18, 2007 By and Between Idera Pharmaceuticals, Inc. And Merck KGaALicense Agreement • March 11th, 2008 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • England
THIS LICENSE AGREEMENT (the “Agreement”) is dated as of December 18, 2007 (the “Signing Date") by and between Idera Pharmaceuticals, Inc., a corporation organized under the laws of Delaware having its place of business at 167 Sidney Street, Cambridge, MA 02139, United States (“Licensor”), and Merck KGaA, a general partnership limited by shares organized under German law having a place of business at Frankfurter Strasse 250, 64293 Darmstadt, Germany (“Merck”). Licensor and Merck may be referred to herein as a “Party” or, collectively, as “Parties.”
CONSULTING AGREEMENTConsulting Agreement • March 11th, 2008 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS CONSULTING AGREEMENT (the “Agreement”), made this 1st day of January, 2008 (“Effective Date”) is entered into by Idera Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 167 Sidney Street, Cambridge, MA 02139 (the “Company”), and Karr Pharma Consulting, LLC, having a place of business located at 30 Ox Bow Lane, Essex, Connecticut 06426 (the “Consultant”). Company and Consultant may be referred to herein individually as a “Party” and collectively as the “Parties.”
